Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights

Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions

(2020) Shiying Shao et al.   PHARMACOLOGY & THERAPEUTICS

Exposure to DPP ‐4 inhibitors and COVID ‐19 among people with type 2 diabetes. A case–control study

(2020) Gian Paolo Fadini et al.   DIABETES OBESITY & METABOLISM

COVID-19 and diabetes: Can DPP4 inhibition play a role?

(2020) Gianluca Iacobellis   DIABETES RESEARCH AND CLINICAL PRACTICE

COVID-19 and diabetes management: What should be considered?

(2020) Antonio Ceriello et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

A NEW ERA FOR THE THERAPEUTIC MANAGEMENT OF THE ONGOING COVID-19 PANDEMIC

(2020) ANDREEA LETIȚIA ARSENE   FARMACIA

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

(2020) Jing Yang et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy

(2020) Giacomo Grasselli et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

(2020) Fei Zhou et al.   LANCET

Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management

(2020) Anca Pantea Stoian et al.   Metabolic Syndrome and Related Disorders

Semaglutide as a promising antiobesity drug

(2019) Georgios A. Christou et al.   Obesity Reviews

Liraglutide treatment reduced interleukin 6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy

(2019) C. Brock et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

An evaluation of liraglutide including its efficacy and safety for the treatment of obesity

(2019) Chen-Hsiu Lin et al.   EXPERT OPINION ON PHARMACOTHERAPY

GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms

(2018) Manfredi Rizzo et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice

(2017) Kun Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials

(2015) Wenjia Yang et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation

(2014) Manfredi Rizzo et al.   CURRENT PHARMACEUTICAL DESIGN

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition

(2009) Mark Kirby et al.   CLINICAL SCIENCE

Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?

(2009) Roger Yazbeck et al.   TRENDS IN PHARMACOLOGICAL SCIENCES